SHAREHOLDER ALERT: WeissLaw LLP Reminds COLB, XLRN, ACBI. and ECHO Shareholders About Its Ongoing Investigations

-

If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:

Joshua Rubin, Esq.
WeissLaw LLP
305 Broadway, 7th Floor
New York, NY 10007
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com

Columbia Banking System, Inc. (NASDAQ: COLB)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Columbia Banking System, Inc. (NASDAQ: COLB) in connection with the proposed merger of the company with Umpqua Holdings Corporation ("Umpqua"). Under the terms of the merger agreement, Umpqua shareholders will receive 0.5958 of a share of COLB stock for each Umpqua share they own, representing implied per-share merger consideration of approximately $20.85 based upon COLB's October 26, 2021 closing price of $34.86 .  If you own COLB shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/colb

Acceleron Pharma Inc. (NASDAQ: XLRN)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Acceleron Pharma Inc. (NASDAQ: XLRN) in connection with the proposed acquisition of the Company by Merck & Co., Inc. ("Merck") (NYSE: MRK), via a tender offer. Under the terms of the merger agreement, XLRN shareholders will receive $180.00 per share in cash for each share of XLRN common stock that they hold.  If you own XLRN shares and wish to discuss this investigation or your rights, please call us or visit our website: https://www.weisslaw.co/news-and-cases/xlrn

Atlantic Capital Bancshares, Inc. (NASDAQ: ACBI)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Atlantic Capital Bancshares, Inc. (NASDAQ: ACBI) in connection with the company's proposed acquisition by SouthState Corporation ("SouthState"). Pursuant to the merger agreement, ACBI shareholders will receive 0.36 shares of South State common stock for each ACBI share that they own, representing implied per-share merger consideration of approximately $27.93 based upon SouthState's October 26, 2021 closing price of $77.59 .  If you own ACBI shares and wish to discuss this investigation or your rights, please call us or visit our website: https://www.weisslaw.co/news-and-cases/acbi

Echo Global Logistics, Inc. (NASDAQ: ECHO)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Echo Global Logistics, Inc. (NASDAQ: ECHO) in connection with the proposed acquisition of the company by funds managed by The Jordan Company, L.P. Under the terms of the merger agreement, ECHO shareholders will receive $48.25 per share in cash for each share of ECHO stock that they hold.  If you own ECHO shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/echo

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-reminds-colb-xlrn-acbi-and-echo-shareholders-about-its-ongoing-investigations-301410246.html

SOURCE WeissLaw LLP

News Provided by Canada Newswire via QuoteMedia

The Conversation (0)
InMed Pharmaceuticals Amends Preferred Investment Options

InMed Pharmaceuticals Amends Preferred Investment Options

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announces that it has entered into amending agreements in respect of... Keep Reading...
Canada maple leaves on left and pharmaceutical pills in red and blue on right.

5 Best-performing Canadian Pharma Stocks in 2026

From established players to up-and-coming firms, Canada's pharmaceutical landscape is diverse and dynamic.Canadian drug companies are working to discover and develop major innovations amid an increasingly competitive global landscape. Rising technologies such as artificial intelligence are... Keep Reading...
Seegnal

Seegnal Inc. Establishes Strategic Commercialization Team and Appoints Arx as Investor Relations Advisor

Seegnal Inc. (TSXV: SEGN) ("Seegnal" or the "Company"), a global leader in clinical decision support solutions applying patient-centric medication safety standards, today announced the formation of a dedicated Strategic Commercialization Team led by its Chief Executive Officer, and the... Keep Reading...
Dollar bills, pink and white pills in blister packs, and a nasal spray on a blue background.

Blackstone Raises Record US$6.3 Billion for Largest Life Sciences Fund

Blackstone (NYSE:BX) has raised US$6.3 billion for its latest life sciences fund, the largest private vehicle dedicated to the sector.The fund, Blackstone Life Sciences VI (BXLS VI), was oversubscribed and closed at its hard cap, about 40 percent larger than its predecessor, which raised US$4.6... Keep Reading...
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors, today announced the Company received a written notice from the Listing Qualifications... Keep Reading...
InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program

InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program

Human Organoid Data Supports the Therapeutic Rationale for INM-901 Program Ahead of Human Clinical TrialsConsistent Anti-Inflammatory Effects Demonstrate Translation from Animal Models to Three-Dimensional Human Brain Tissue SystemsInMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the... Keep Reading...

Interactive Chart

Latest Press Releases

Related News